FGF7, fibroblast growth factor 7, 2252

N. diseases: 167; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011603
Disease: Dermatitis
Dermatitis
0.010 Biomarker disease BEFREE In vivo, the BALB/c mouse psoriasis model established by topical application of imiquimod (IMQ) was used to determine the role of FGF-7-specific antibody (F-9) in skin inflammation. 31555794 2019
CUI: C0024312
Disease: Lymphopenia
Lymphopenia
0.010 Biomarker disease BEFREE Keratinocyte growth factor impairs human thymic recovery from lymphopenia. 31063156 2019
CUI: C0085109
Disease: Corneal Neovascularization
Corneal Neovascularization
0.010 Biomarker disease BEFREE The aim of the present study was to evaluate the ability of HGF and KGF to influence VEGF and its receptor, kinase insert domain receptor (Flk‑1) in corneal injury and CNV in rats induced by ultraviolet radiation (UVR). 30816491 2019
CUI: C2973725
Disease: Pulmonary arterial hypertension
Pulmonary arterial hypertension
0.010 AlteredExpression disease BEFREE Mir-455-3p-1 represses FGF7 expression to inhibit pulmonary arterial hypertension through inhibiting the RAS/ERK signaling pathway. 30858037 2019
Idiopathic pulmonary arterial hypertension
0.010 AlteredExpression disease BEFREE FGF7 was upregulated in PAH.MiR-455-3p-1 was downregulated in PAH.MiR-455-3p-1 targeted FGF7. 30858037 2019
CUI: C4728046
Disease: Diabetic wound
Diabetic wound
0.010 Biomarker disease BEFREE Improved stability of KGF by conjugation with gold nanoparticles for diabetic wound therapy. 31791171 2019
CUI: C0002170
Disease: Alopecia
Alopecia
0.010 AlteredExpression disease BEFREE The results demonstrated that the mechanism of BT improving alopecia is potentially associated with modulation of EGF and FGF‑7 levels. 29693180 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.010 AlteredExpression group BEFREE Western blot of lung tissue confirmed high expression of KGF and their target molecules (interleukin-6, protein kinase B, and B-cell lymphoma-2) in the Muse group. 29707971 2018
CUI: C0149882
Disease: Acute esophagitis
Acute esophagitis
0.010 Biomarker disease BEFREE Chemotherapy (P < .001) and baseline keratinocyte growth factor (P = .019) predicted acute esophagitis, but only chemotherapy remained significant after Bonferroni correction. 29398577 2018
CUI: C0677886
Disease: Epithelial ovarian cancer
Epithelial ovarian cancer
0.010 Biomarker disease BEFREE The effect of KGF in promoting EOC cell invasion was blocked by an FGFR2-IIIb antibody. 29970688 2018
CUI: C0015967
Disease: Fever
Fever
0.010 GeneticVariation phenotype BEFREE The two adverse events assessed as related to KGF were due to pyrexia. 28526233 2017
CUI: C0016781
Disease: Fuchs Endothelial Dystrophy
Fuchs Endothelial Dystrophy
0.010 Biomarker disease BEFREE Higher percentages of stromal cells in FECD versus normal stained for αSMA (OR = 864.26, P < 0.001), brain-derived neurotrophic factor (BDNF, OR = 6.34, P = 0.005), fibroblast growth factor 7 (FGF-7, OR = 2.76, P = 0.011), FGF-9 (OR = 5.97, P < 0.001), receptor FGFR-3 (OR = 13.90, P = < 0.001), and serum amyloid A1 (OR = 3.45, P = 0.023). 28481834 2017
CUI: C0042769
Disease: Virus Diseases
Virus Diseases
0.010 Biomarker group BEFREE Coadministration of KGF with IAV markedly accelerated the spread of viral infection from the airways to alveoli compared with challenge with IAV alone, based on spatial and temporal analyses of viral nucleoprotein staining of lung tissue sections and dissociated lung cells. 28739896 2017
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.010 Biomarker phenotype BEFREE Our results indicated that the abnormal behavior of the cholesteatoma epithelium seems to be induced by the paracrine interaction between KGF and KGFR. 29556625 2017
CUI: C0271441
Disease: Chronic otitis media
Chronic otitis media
0.010 Biomarker disease BEFREE The purpose of this study was to investigate the potential influence of KGF and KGFR in increased epithelial-cell proliferation of chronic otitis media (COM) with cholesteatoma in contrast to COM without cholesteatoma (CSOM), particularly in the granulative form, and to compare the rate of proliferation activity of epithelial cells using the Ki-67 epithelial proliferation marker expression. 29556625 2017
CUI: C0271454
Disease: Chronic purulent otitis media
Chronic purulent otitis media
0.010 Biomarker disease BEFREE KGF was positive in 88.57% of cholesteatoma and was positive in 41.51% CSOM without cholesteatoma specimens (cholesteatoma vs. CSOM, p=0.001). 29556625 2017
CUI: C0748355
Disease: Acute respiratory distress
Acute respiratory distress
0.010 Biomarker disease BEFREE Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. 28526233 2017
CUI: C2062441
Disease: Influenza A
Influenza A
0.010 Biomarker disease BEFREE To better define the temporal relationship between KGF administration and susceptibility to IAV infection in vivo, we administered KGF 120, 48, 24, and 0 h before intrapulmonary IAV challenge and assessed the percentages of proliferating and IAV-infected, alveolar type II (AECII) cells in dispersed lung cell populations. 28739896 2017
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.010 Biomarker disease BEFREE In in vitro assay, KGF promoted colon cancer cell growth, as well as up-regulated and activated AhR. 26514676 2016
CUI: C0023895
Disease: Liver diseases
Liver diseases
0.010 AlteredExpression group BEFREE We examined the correlation of the levels of miR-219-5p and KGF in the liver biopsies from patients with liver diseases. 27855391 2016
CUI: C0085423
Disease: Gram-Negative Bacterial Infections
Gram-Negative Bacterial Infections
0.010 Biomarker group BEFREE In this study we tested the hypothesis that endogenous KGF plays a role in the maintenance of innate pulmonary defense against gram-negative bacterial infections. 26919897 2016
CUI: C0007138
Disease: Carcinoma, Transitional Cell
Carcinoma, Transitional Cell
0.010 AlteredExpression disease BEFREE We then used our well characterized urothelial carcinoma cohort to analyze FGF7 transcript and protein expression, and its clinicopathological significance. 25623741 2015
Transitional cell carcinoma of bladder
0.010 AlteredExpression disease BEFREE An increased FGF7 transcript level was associated with higher pT stage in upper tract and bladder urothelial carcinoma (p = 0.003 and <0.001, respectively). 25623741 2015
Secondary malignant neoplasm of lymph node
0.010 AlteredExpression disease BEFREE In the upper tract and bladder carcinoma groups FGF7 protein over expression was also significantly associated with advanced pT status (each p <0.001), lymph node metastasis (p = 0.002 and <0.001), high histological grade (p = 0.019 and <0.001), vascular invasion (each p <0.001), perineural invasion (p = 0.002 and 0.021) and frequent mitoses (p = 0.002 and 0.042, respectively). 25623741 2015
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.010 AlteredExpression disease BEFREE In the upper tract and bladder carcinoma groups FGF7 protein over expression was also significantly associated with advanced pT status (each p <0.001), lymph node metastasis (p = 0.002 and <0.001), high histological grade (p = 0.019 and <0.001), vascular invasion (each p <0.001), perineural invasion (p = 0.002 and 0.021) and frequent mitoses (p = 0.002 and 0.042, respectively). 25623741 2015